Procept's Anti-HIV Drug In Phase I/II
Specialist in immune system therapeutics Procept has started Phase I/II clinical trials for its leading drug candidate PRO 2000, a compound intended for the treatment of HIV-1.
The study will be conducted in Amsterdam and will evaluate the safety, tolerability and antiviral activity of the drug in HIV-infected patients in a dose-escalating manner. Preliminary data suggest the drug was well-tolerated in a healthy-volunteer, dose- ranging study. Further to this, preclinical studies have shown PRO 2000 to block the binding of gp120, an HIV surface glycoprotein, to its cellular target, the CD4 protein.
Procept believes that by binding to CD4, PRO 2000 may act as a molecular (mechanical) barrier to block HIV from infecting its target immune system cells, including T cells and macrophages. In addition, the company is optimistic that the drug, because of the nature of its mechanism of action, is less likely to lead to drug resistance than other HIV treatments.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze